IGFBP6 and fibrosis: Dermal fibroblasts treated with a combination of TGF-β1 and the monocyte chemoattractant protein 3 (MCP-3), a protein that is up-regulated in fibrosis, led to a high and significant IGFBP-6 upregulation [39].